Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) has announced its participation in the 29th Annual Congress of the World Muscle Society, taking place from October 8-12, 2024, in Prague, Czechia. The company will present three posters focusing on its Pompe disease development program:

1. Cipaglucosidase alfa + miglustat in late-onset Pompe disease: Two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa

2. Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease

3. Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease

All posters will be presented on Friday, October 11, from 3:45 – 4:45 p.m. CET in the Forum Hall of The Prague Congress Centre.

Positive

• Amicus Therapeutics is presenting three posters at a major industry conference, showcasing its Pompe disease development program
• The company's research focuses on innovative treatments for late-onset Pompe disease, including cipaglucosidase alfa + miglustat and a first-in-class enzyme stabilizer

Negative

• None.

News Market Reaction

+0.38%

1 alert

+0.38% News Effect

On the day this news was published, FOLD gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.

Poster Session: Pompe Disease

Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P)

• Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre
  

Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #670P)

• Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre
  

Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #671P)

• Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
• Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
• Location: Forum Hall, The Prague Congress Centre
  

For more information on the WMS 2024 Annual Congress, please visit www.wms2024.com

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

What is Amicus Therapeutics (FOLD) presenting at the World Muscle Society Annual Congress 2024?

Amicus Therapeutics is presenting three posters on its Pompe disease development program, including studies on cipaglucosidase alfa + miglustat in late-onset Pompe disease, post-baseline outcomes of a UK registry, and miglustat as a first-in-class enzyme stabilizer.

When and where is the World Muscle Society Annual Congress 2024 taking place?

The 29th Annual Congress of the World Muscle Society is being held from October 8-12, 2024, in Prague, Czechia.

What specific treatments for Pompe disease is Amicus Therapeutics (FOLD) showcasing at the conference?

Amicus Therapeutics is showcasing treatments including cipaglucosidase alfa + miglustat for late-onset Pompe disease, and miglustat as a first-in-class enzyme stabilizer for late-onset Pompe disease.

When are the Amicus Therapeutics (FOLD) posters being presented at the World Muscle Society Annual Congress 2024?

All three posters will be presented on Friday, October 11, 2024, from 3:45 – 4:45 p.m. CET in the Forum Hall of The Prague Congress Centre.